• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Section Contents Menu

Drug Safety and Availability

FDA Drug Safety Newsletter - Volume 2, Number 2, 2009

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.

In This Issue

Editor's Note

Postmarket Reviews

Overview of off-label use and serious adverse events 

Reports of acute renal impairment and failure associated with once-yearly intravenous treatment for osteoporosis in postmenopausal women

Reports of medication errors and adverse events in a pediatric population


Lenalidominde and Serious Skin Reactions - Drug Safety Newsletter 2008; 1 (4); 43-6.

Drug Safety Communications

List of drug safety advisories posted on FDA’s Web site from December 1, 2008 through March 31, 2009, with related links

 Cover of Newsletter, including table of contents